Phase II
MetrioPharm AG, a clinical stage biopharmaceutical company, reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients.
Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.
With No Safety Concerns, DSMB Recommends Trial Continues; Dose Increase Planned
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
Summit Therapeutics plc announced the presentation of new data that explain the link between two key findings in the Company’s Phase 2 clinical trial of ridinilazole for C. difficile infection
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
Target number of clinical sites reached, including leading hospitals and geriatric centers in the US and Europe Patient enrollment expected to complete in mid-2020
It was another busy week for clinical trials. Here’s a look.
PRESS RELEASES